Switch theme
Sign up to access all valuation multiples
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
1996
405
LTM Revenue $299M
LTM EBITDA $37.7M
$798M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Dynavax has a last 12-month revenue (LTM) of $299M and a last 12-month EBITDA of $37.7M.
In the most recent fiscal year, Dynavax achieved revenue of $277M and an EBITDA of $45.7M.
Dynavax expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Dynavax valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $299M | XXX | $277M | XXX | XXX | XXX |
| Gross Profit | $242M | XXX | $228M | XXX | XXX | XXX |
| Gross Margin | 81% | XXX | 82% | XXX | XXX | XXX |
| EBITDA | $37.7M | XXX | $45.7M | XXX | XXX | XXX |
| EBITDA Margin | 13% | XXX | 16% | XXX | XXX | XXX |
| EBIT | $2.6M | XXX | -$4.1M | XXX | XXX | XXX |
| EBIT Margin | 1% | XXX | -1% | XXX | XXX | XXX |
| Net Profit | $5.0M | XXX | $27.3M | XXX | XXX | XXX |
| Net Margin | 2% | XXX | 10% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $128M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Dynavax's stock price is $10.
Dynavax has current market cap of $1.2B, and EV of $798M.
See Dynavax trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $798M | $1.2B | XXX | XXX | XXX | XXX | $0.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Dynavax has market cap of $1.2B and EV of $798M.
Dynavax's trades at 2.9x EV/Revenue multiple, and 17.5x EV/EBITDA.
Equity research analysts estimate Dynavax's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Dynavax has a P/E ratio of 233.7x.
See valuation multiples for Dynavax and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV (current) | $798M | XXX | $798M | XXX | XXX | XXX |
| EV/Revenue | 2.7x | XXX | 2.9x | XXX | XXX | XXX |
| EV/EBITDA | 21.2x | XXX | 17.5x | XXX | XXX | XXX |
| EV/EBIT | 305.7x | XXX | -193.6x | XXX | XXX | XXX |
| EV/Gross Profit | 3.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 233.7x | XXX | 43.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 13.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDynavax's last 12 month revenue growth is 18%
Dynavax's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.6M for the same period.
Dynavax's rule of 40 is 22% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Dynavax's rule of X is 57% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Dynavax and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 18% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Margin | 13% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Growth | -35% | XXX | 35% | XXX | XXX | XXX |
| Rule of 40 | 22% | XXX | 34% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 57% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 22% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 84% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Dynavax acquired XXX companies to date.
Last acquisition by Dynavax was XXXXXXXX, XXXXX XXXXX XXXXXX . Dynavax acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Dynavax founded? | Dynavax was founded in 1996. |
| Where is Dynavax headquartered? | Dynavax is headquartered in United States of America. |
| How many employees does Dynavax have? | As of today, Dynavax has 405 employees. |
| Who is the CEO of Dynavax? | Dynavax's CEO is Mr. Ryan Spencer. |
| Is Dynavax publicy listed? | Yes, Dynavax is a public company listed on NAS. |
| What is the stock symbol of Dynavax? | Dynavax trades under DVAX ticker. |
| When did Dynavax go public? | Dynavax went public in 2004. |
| Who are competitors of Dynavax? | Similar companies to Dynavax include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Dynavax? | Dynavax's current market cap is $1.2B |
| What is the current revenue of Dynavax? | Dynavax's last 12 months revenue is $299M. |
| What is the current revenue growth of Dynavax? | Dynavax revenue growth (NTM/LTM) is 18%. |
| What is the current EV/Revenue multiple of Dynavax? | Current revenue multiple of Dynavax is 2.7x. |
| Is Dynavax profitable? | Yes, Dynavax is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Dynavax? | Dynavax's last 12 months EBITDA is $37.7M. |
| What is Dynavax's EBITDA margin? | Dynavax's last 12 months EBITDA margin is 13%. |
| What is the current EV/EBITDA multiple of Dynavax? | Current EBITDA multiple of Dynavax is 21.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
